A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.

A Randomized, Placebo-controlled, Double-masked, Multi-center, Dose-ranging Study to Evaluate the Safety, and Efficacy of UNR844 in Subjects With Presbyopia

ClinicalTrials.gov Identifier: NCT04806503

Novartis Reference Number: CUNR844A2202

Last Update: May 24, 2022

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

Study of safety and efficacy of UNR844 in subjects with presbyopia.

Condition

Presbyopia

Phase

Phase 2

Overall status

Recruiting

Start date

Jun 30, 2021

Completion date

Apr 10, 2023

Gender

All

Age(s)

45 Years - 55 Years (Adult)

Interventions

Drug

UNR844

Ophthalmic solution for topical ocular administration

Drug

Placebo

Eligibility Criteria

Inclusion Criteria:

Written informed consent must be obtained before any assessment is performed
Impaired near vision in each eye and when using both eyes, without any near correction
Need a certain level of near correction

Exclusion Criteria:

Impaired distance vision in either eye, with distance correction (if any)
Severe short- or long-sightedness
Any significant medical or clinical conditions affecting vision, the eyes or general health